Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1654510

registered interest
date	19/07/2023
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Afghanistan: Women
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps he plans to take in response to the report A/HRC/53/21: Situation of women and girls in Afghanistan - Report of the Special Rapporteur on the situation of human rights in Afghanistan and the Working Group on discrimination against women and girls.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	195080
answer	answer is ministerial correction date of answer 04/09/2023 answer text <p>The UK Government is grateful for the report of the Special Rapporteur and the working group which sheds further light on the Taliban's severe restrictions on the rights of women and girls in Afghanistan. Officials are considering the report's recommendations.</p><p>We have repeatedly condemned the Taliban's decisions to restrict the rights of women and girls, including through the UN Security Council, Human Rights Council resolutions and public statements. We continue to work with the international community to press the Taliban to reverse their harmful policies.</p> answering member constituency Aldershot answering member printed Leo Docherty question first answered 04/09/2023 16:14:55 answering member 4600 label Biography information for Leo Docherty
tabling member	4124 label Biography information for Chi Onwurah

1013182

registered interest
date	23/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Cost Effectiveness
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 October 2018 to Question 181572 on Drugs: Cost Effectiveness, if he will place in the Library the 27 topics that have triggered the £20 million budget impact test.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	195080
answer	answer is ministerial correction date of answer 03/12/2018 answer text <p>The information requested can be found in the following table.</p><table><tbody><tr><td><p> </p></td><td><p>Topic Title</p></td><td><p>Programme</p></td></tr><tr><td><p>1</p></td><td><p>Afamelanotide for treating erythropoietic protoporphyria [ID927]</p></td><td><p>HST (highly specialised technology)</p></td></tr><tr><td><p>2</p></td><td><p>Niraparib for maintenance treatment of platinum-sensitive ovarian cancer after second response to chemotherapy [ID1041]</p></td><td><p>TA (technology appraisal)</p></td></tr><tr><td><p>3</p></td><td><p>Lenalidomide for previously untreated multiple myeloma [ID474]</p></td><td><p>TA</p></td></tr><tr><td><p>4</p></td><td><p>Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048]</p></td><td><p>TA</p></td></tr><tr><td><p>5</p></td><td><p>Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (Cancer Drugs Fund Review of TA447) [ID1349]</p></td><td><p>TA</p></td></tr><tr><td><p>6</p></td><td><p>Abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]</p></td><td><p>TA</p></td></tr><tr><td><p>7</p></td><td><p>Pertuzumab for adjuvant treatment of early HER2-positive breast cancer [ID1192]</p></td><td><p>TA</p></td></tr><tr><td><p>8</p></td><td><p>Burosumab for treating X-linked hypophosphataemia [ID1151]</p></td><td><p>HST</p></td></tr><tr><td><p>9</p></td><td><p>Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more systemic therapies [ID1115]</p></td><td><p>TA</p></td></tr><tr><td><p>10</p></td><td><p>Ocrelizumab for treating primary progressive multiple sclerosis [ID938]</p></td><td><p>TA</p></td></tr><tr><td><p>11</p></td><td><p>Daratumumab in combination with bortezomib for treating relapsed or refractory multiple myeloma [ID974]</p></td><td><p>TA</p></td></tr><tr><td><p>12</p></td><td><p>Nusinersen for treating spinal muscular atrophy [ID1069]</p></td><td><p>TA</p></td></tr><tr><td><p>13</p></td><td><p>Dabrafenib in combination with trametinib for adjuvant treatment of resected BRAF V600 positive malignant melanoma [ID1226]</p></td><td><p>TA</p></td></tr><tr><td><p>14</p></td><td><p>Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316]</p></td><td><p>TA</p></td></tr><tr><td><p>15</p></td><td><p>Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (including a review of TA381) [ID1296]</p></td><td><p>TA</p></td></tr><tr><td><p>16</p></td><td><p>Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies [ID1166]</p></td><td><p>TA</p></td></tr><tr><td><p>17</p></td><td><p>Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer [ID1227]</p></td><td><p>TA</p></td></tr><tr><td><p>18</p></td><td><p>Pembrolizumab for adjuvant treatment of melanoma with high risk of recurrence [ID1266]</p></td><td><p>TA</p></td></tr><tr><td><p>19</p></td><td><p>Human alpha1-proteinase inhibitor for treating emphysema [ID856]</p></td><td><p>HST</p></td></tr><tr><td><p>20</p></td><td><p>Pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer [ID1173]</p></td><td><p>TA</p></td></tr><tr><td><p>21</p></td><td><p>Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]</p></td><td><p>TA</p></td></tr><tr><td><p>22</p></td><td><p>Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]</p></td><td><p>TA</p></td></tr><tr><td><p>23</p></td><td><p>Patisiran for treating hereditary transthyretin amyloidosis [ID1279]</p></td><td><p>HST</p></td></tr><tr><td><p>24</p></td><td><p>Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]</p></td><td><p>TA</p></td></tr><tr><td><p>25</p></td><td><p>Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID1175]</p></td><td><p>New TA process</p></td></tr><tr><td><p>26</p></td><td><p>Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]</p></td><td><p>New TA process</p></td></tr><tr><td><p>27</p></td><td><p>Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359]</p></td><td><p>TA</p></td></tr></tbody></table><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/12/2018 17:38:05 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

46703

registered interest
date	03/04/2014
answering body	Attorney General
answering dept id	88
answering dept short name	Attorney General
answering dept sort name	Attorney General
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Attorney General, how and on what basis the Crown Prosecution Service decides whether to prioritise the allocation of resources to its decision-making on criminal charges following conclusions of unlawful killing at an inquest or public inquiry; and whether there is additional consideration where the events in question occurred more than three years prior to the conclusion of the inquest or public inquiry.
tabling member constituency	Feltham and Heston
tabling member printed	Seema Malhotra
uin	195080
answer	answer is ministerial correction date of answer 09/04/2014 answer text <p>The Crown Prosecution Service (CPS) will consider whether there is any new evidence or information within the coroner's proceedings which may have an impact upon any previous CPS decision not to bring criminal charges against an individual(s) or organisation following a conclusion of unlawful killing at an inquest or public inquiry. Where it is found that a further investigation will need to be conducted by the police, and a fresh decision made by the CPS, the police and CPS should ensure the Coroner and bereaved family / next of kin are notified of the next steps to be taken.</p><p>The allocation of CPS resources to make decisions on criminal charges will be determined by the specific facts and circumstances of the individual case. The Complex Casework Units in each of the CPS Areas will deal with more complex homicide cases; other homicide cases will be handled by senior prosecutors in the Areas. The Special Crime and Counter Terrorism Division in CPS headquarters also deals with a wide range of homicide cases including deaths in custody, assisted suicides, terrorist-related homicides and homicides arising from so-called ‘disaster' cases. There are no additional considerations where the events in question occurred more than three years prior to the conclusion of the inquest or public inquiry.</p><p> </p> answering member constituency North East Hertfordshire answering member printed Oliver Heald question first answered 09/04/2014 12:00:00 answering member 69 label Biography information for Sir Oliver Heald
tabling member	4253 label Biography information for Seema Malhotra